ClinicalTrials.gg
CompletedNCT01774968Updated Sep 22, 2015Results posted

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

A Phase 4 interventional study of Human Regular U-500 Insulin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 39 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-22.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
325
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
16th of 49
325 · median 129
Started
2013
the only one that year
Phase 4
7 of 49
none open now
Registered
39th of 49
by date
Lead sponsor
7 of 49
Eli Lilly and Company

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is the only one that started in 2013, is one of 7 in phase 4, and was the 39th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The main purpose of this study is to compare the effectiveness of Human Regular U-500 Insulin three times a day versus twice a day.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Have type 2 diabetes mellitus (World Health Organization [WHO] Classification of Diabetes)
  • Have a (BMI) ≥25 kilogram per square meter (kg/m\^2)
  • Have A1c (HbA1c) ≥7.5% and ≤12.0%, as measured by the central laboratory at entry
  • Current U-100 insulin/analogue users on >200 and ≤600 units per day for ≥3 months at study entry and reconfirmed at randomization
  • Have a history of stable body weight for at least 3 months prior to study entry
  • Concomitant medications may include metformin (MET), dipeptidyl peptidase-4 (DPP-4) inhibitors approved for use with insulin at time of study entry (for example, sitagliptin, saxagliptin, and linagliptin), pioglitazone, and/or sulfonylureas (SUs)/glinides (repaglinide or nateglinide). Participant's oral antihyperglycemic drug (OAD) dose(s) must have been stable for ≥3 months

Major Exclusion Criteria:

  • Have type 1 diabetes mellitus or other types of diabetes mellitus apart from type 2 diabetes mellitus
  • Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or or aspartate aminotransferase levels ≥3 times the upper limit of the reference range
  • Have chronic kidney disease stage 4 and higher or history of renal transplantation
  • Have history of more than 1 episode of severe hypoglycemia within the 6 months prior to study entry
  • Have received insulin by continuous subcutaneous insulin infusion in the 3 months prior to study entry
  • Have received U-500R in the 3 months prior to study entry
  • Have had a blood transfusion or severe blood loss within 3 months prior to study entry or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia
  • Are taking chronic systemic therapy or have received such therapy within the 4 weeks immediately prior to study entry
  • Have an irregular sleep/wake cycle
  • Have used rosiglitazone, once- or twice-daily glucagon-like peptide-1 (GLP-1) receptor agents, pramlintide, or other injectable or oral antihyperglycemic therapy not listed in the inclusion criteria in the 3 months prior to study entry. Participants may not have used once-weekly GLP-1 receptor agents in the 4 months prior to study entry
  • Have used any weight loss drugs in the 3 months prior to study entry
  • Have a history of bariatric surgery
  • Have a history of other than basal cell or squamous cell skin cancer
  • Have (NYHA) Class III or IV per NYHA Cardiac Disease Functional Classification
  • Are breastfeeding or pregnant, or intend to become pregnant during the course of the study, or are sexually active women of not actively practicing by a method determined by the investigator to be medically acceptable
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
325 participants (actual)

Study arms

  • Experimental
    Human Regular U-500 Insulin TID

    Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.

    Drug: Human Regular U-500 Insulin

  • Experimental
    Human Regular U-500 Insulin BID

    U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.

    Drug: Human Regular U-500 Insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)

    Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Achieving HbA1c of ≤6.5%, <7.0%, <7.5%, and <8.0% at Week 24

    The percentage of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.

    Time frame: Week 24

  2. 30-Day Adjusted Rate of Hypoglycemic Events

    Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through Week 24

  3. Change From Baseline to Week 24 in Body Weight

    LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.

    Time frame: Baseline, Week 24

  4. Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin

    Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.

    Time frame: Baseline, Week 24

  5. Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin

    Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.

    Time frame: Baseline, Week 24

  6. Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels

    LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.

    Time frame: Baseline, Week 24

  7. Time to Reach HbA1c Target Values

    The cumulative number of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.

    Time frame: Baseline through 6, 12, 18, and 24 weeks.

  8. Percentage of Participants With Hypoglycemic Events

    Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through Week 24

  9. Change From Baseline to Week 24 in Number of Insulin Injections

    The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.

    Time frame: Baseline, Week 24

  10. Mean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)

    The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.

    Time frame: Baseline, Week 24

  11. Change From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg

    Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.

    Time frame: Baseline, Week 24

  12. Change From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg

    Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline, Week 24

  13. Change From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg

    Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or \>2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (\>300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.

    Time frame: Baseline, Week 24

  14. Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg

    Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.

    Time frame: Baseline, Week 24

07

Results

Posted May 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Started162163
Received at least 1 dose of study drug162161
Completed132128
Not completed3035
Withdrew: Adverse event44
Withdrew: Death01
Withdrew: Lost to follow-up13
Withdrew: Physician decision51
Withdrew: Protocol violation1413
Withdrew: Sponsor decision02
Withdrew: Withdrawal by subject611

Outcome measures

PrimaryChange From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)

Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with investigator, baseline total daily dose (TDD; ≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)
percentage of HbA1cHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Change From Baseline to Week 24 in Glycated Hemoglobin A1c (HbA1c)-1.12 ± 0.08-1.22 ± 0.08
Statistical analysis
  • Human Regular U-500 Insulin TID vs Human Regular U-500 Insulin BID · Mixed Models Analysis · p = 0.3709 · Ls mean difference: -0.10 · 95% CI -0.33 to 0.12
SecondaryPercentage of Participants Achieving HbA1c of ≤6.5%, <7.0%, <7.5%, and <8.0% at Week 24

The percentage of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% at Week 24 was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving HbA1c of ≤6.5%, <7.0%, <7.5%, and <8.0% at Week 24
percentage of participantsHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
HbA1c ≤6.5% (n=159, 161)20.1323.60
HbA1c <7.0% (n=158, 159)42.4141.51
HbA1c <7.5% (n=148, 143)64.1961.54
HbA1c <8.0% (n=120, 123)77.5077.24
Secondary30-Day Adjusted Rate of Hypoglycemic Events

Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through Week 24
Reported as:
Mean · events per participant per 30 days
30-Day Adjusted Rate of Hypoglycemic Events
events per participant per 30 daysHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Severe HE0.004 ± 0.0280.009 ± 0.053
Documented Symptomatic HE3.343 ± 3.1743.885 ± 3.448
Documented Symptomatic Nocturnal HE1.013 ± 1.4381.299 ± 1.540
Asymptomatic HE1.340 ± 3.2151.028 ± 2.231
SecondaryChange From Baseline to Week 24 in Body Weight

LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline to Week 24 in Body Weight
kilograms (kg)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Change From Baseline to Week 24 in Body Weight5.44 ± 0.414.88 ± 0.41
SecondaryChange From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin

Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units
Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin
unitsHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Change From Baseline to Week 24 in Total Daily Dose (TDD; Units) of Insulin55.19 ± 10.1651.39 ± 10.24
SecondaryChange From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin

Baseline TDD was defined as the last U-100 insulin TDD prior to receiving the first dose of U-500R insulin. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline TDD as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units per kilogram (units/kg)
Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin
units per kilogram (units/kg)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Change From Baseline to Week 24 in Total Daily Dose (TDD; Units/kg) of Insulin0.32 ± 0.080.32 ± 0.08
SecondaryChange From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels

LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline FPG as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels
milligrams per deciliter (mg/dL)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Change From Baseline to Week 24 in Fasting Plasma Glucose (FPG) Levels-6.66 ± 5.64-8.86 ± 5.72
SecondaryTime to Reach HbA1c Target Values

The cumulative number of participants achieving an HbA1c of ≤6.5%, \<7.0%, \<7.5%, and \<8.0% is summarized at Weeks 6, 12, 18, and 24. The number of participants at risk (n) is also provided for each target value and timepoint.

Time frame:
Baseline through 6, 12, 18, and 24 weeks.
Reported as:
Number · participants
Time to Reach HbA1c Target Values
participantsHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
HbA1c ≤6.5%, Week 6 (n=154, 155)16
HbA1c ≤6.5%, Week 12 (n=145, 151)1515
HbA1c ≤6.5%, Week 18 (n=140, 145)2427
HbA1c ≤6.5%, Week 24 (n=76, 65)2837
HbA1c <7.0%, Week 6 (n=154, 153)1410
HbA1c <7.0%, Week 12 (n=148, 149)3136
HbA1c <7.0%, Week 18 (n=144, 145)5255
HbA1c <7.0%, Week 24 (n=53, 52)6065
HbA1c <7.5%, Week 6 (n=144, 137)3020
HbA1c <7.5%, Week 12 (n=140, 134)5959
HbA1c <7.5%, Week 18 (n=136, 132)8178
HbA1c <7.5%, Week 24 (n=34, 31)9087
HbA1c <8.0%, Week 6 (n=117, 117)3234
HbA1c <8.0%, Week 12 (n=114, 115)6672
HbA1c <8.0%, Week 18 (n=111, 113)8586
HbA1c <8.0%, Week 24 (n=20, 19)8995
SecondaryPercentage of Participants With Hypoglycemic Events

Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), documented symptomatic nocturnal (any documented symptomatic HE that occurred between bedtime and waking), or asymptomatic (any measured PG ≤70 mg/dL not accompanied by hypoglycemic signs/symptoms). The percentage of participants with HE at 24 weeks was calculated by the dividing the number of participants meeting the criteria by the total number of participants analyzed, multiplied by 100. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Hypoglycemic Events
percentage of participantsHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Severe HE1.853.73
Documented Symptomatic HE91.9890.06
Documented Symptomatic Nocturnal HE77.7880.75
Asymptomatic HE64.2066.46
SecondaryChange From Baseline to Week 24 in Number of Insulin Injections

The number of insulin injections per day at baseline (Week 0) and at Week 24 are presented.

Time frame:
Baseline, Week 24
Reported as:
Mean · injections per day
Change From Baseline to Week 24 in Number of Insulin Injections
injections per dayHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Baseline4.765 ± 1.2344.783 ± 1.307
Week 243.000 ± 0.0002.000 ± 0.000
SecondaryMean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)

The 7-point SMBG is a participant self-administered blood glucose test which utilizes measurements at specific time points over a 24-hour period, including pre-morning meal (fasting), 2 hours after morning meal, pre-midday meal, 2 hours after midday meal, pre-evening meal, 2 hours after evening meal, and 3 AM. LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline SMBG as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mg/dL
Mean Change From Baseline to Week 24 in 7-Point Self-Monitored Blood Glucose (SMBG)
mg/dLHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Pre-morning Meal (n=150, 149)-24.10 ± 3.96-29.19 ± 3.91
2 Hours After Morning Meal (n=146, 133)-21.68 ± 4.29-31.32 ± 4.29
Pre-midday Meal (n=150, 149)-23.54 ± 4.17-32.26 ± 4.11
2 Hours After Midday Meal (n=143, 133)-24.31 ± 4.50-22.53 ± 4.49
Pre-evening Meal (n=150, 149)-34.17 ± 3.93-32.96 ± 3.85
2 Hours After Evening Meal (n=147, 142)-40.56 ± 4.13-38.36 ± 4.11
3 AM (n=147, 140)-36.77 ± 4.34-47.82 ± 4.29
SecondaryChange From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg

Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline HbA1c as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline to Week 24 in HbA1c Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg
percentage of HbA1cHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Baseline TDD ≤2.0 units/kg (n=50, 46)-0.99 ± 0.14-1.32 ± 0.15
Baseline TDD >2.0 units/kg (n=112, 115)-1.19 ± 0.10-1.18 ± 0.10
SecondaryChange From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg

Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). Hypoglycemic events (HE) were classified as severe (an event requiring assistance from another person \[accompanied by neurologic/cognitive impairment\]), documented symptomatic (DS; an event which is associated with signs/symptoms of hypoglycemia and plasma glucose \[PG\] ≤70 milligrams per deciliter \[mg/dL\]), or nocturnal (Noc; any documented symptomatic HE that occurred between bedtime and waking). The 30-day adjusted rate of HE is summarized cumulatively at 24 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline, Week 24
Reported as:
Mean · events per participant per 30 days
Change From Baseline to Week 24 in 30-Day Adjusted Rate of Hypoglycemic Events Based on Baseline TDD Insulin ≤2.0 Units/kg and >2.0 Units/kg
events per participant per 30 daysHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Severe HE, TDD ≤2 units/kg, Baseline (n=50, 46)0 ± 00 ± 0
Severe HE, TDD ≤2 units/kg, Week 24 (n=50, 46)0.004 ± 0.0250 ± 0
Severe HE, TDD >2 units/kg, Baseline (n=112, 115)0 ± 00 ± 0
Severe HE, TDD >2 units/kg, Week 24 (n=112, 115)0.004 ± 0.0290.013 ± 0.062
DS HE, TDD ≤2 units/kg, Baseline (n=50, 46)1.958 ± 4.8081.454 ± 3.251
DS HE, TDD ≤2 units/kg, Week 24 (n=50, 46))2.356 ± 2.3523.131 ± 3.204
DS HE, TDD >2 units/kg, Baseline (n=112, 115)2.037 ± 4.3821.730 ± 3.180
DS HE, TDD >2 units/kg, Week 24 (n=112, 115)3.784 ± 3.3974.186 ± 3.509
Noc. HE, TDD ≤2 units/kg, Baseline (n=50, 46)1.066 ± 2.0450.711 ± 1.965
Noc. HE, TDD ≤2 units/kg, Week 24 (n=50, 46)1.105 ± 1.1531.282 ± 1.431
Noc. HE, TDD >2 units/kg, Baseline (n=112, 115)0.792 ± 2.4650.585 ± 1.445
Noc. HE, TDD >2 units/kg, Week 24 (n=112, 115)1.522 ± 2.0181.753 ± 1.934
SecondaryChange From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg

Participants were stratified by their baseline TDD insulin (≤2.0 units (U)/kg or \>2.0 U/kg). The percentage of participants at risk of developing hypoglycemia (including documented symptomatic, asymptomatic, probable symptomatic, unspecified, or severe hypoglycemia) is presented at Baseline and at Week 24 and was calculated using MMRM fit with options of the binomial distribution and log link function including treatment, TDD (\>300 units or ≤300 units), pioglitazone use (yes or no), visit, and treatment-by-visit interaction as fixed effects, and baseline HbA1c value as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Change From Baseline to Week 24 in Percentage of Participants With Hypoglycemic Events Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg
percentage of participantsHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Baseline TDD≤2.0 U/kg, Baseline risk (n=50, 46)56.0039.13
Baseline TDD ≤2.0 U/kg, Week 24 risk (n=50, 46)94.0086.96
Baseline TDD >2.0 U/kg, Baseline risk (n=112, 115)47.3251.30
Baseline TDD >2.0 U/kg, Week 24 risk (n=112, 115)96.4397.39
SecondaryChange From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg

Participants were stratified by their baseline TDD insulin (≤2.0 units/kg or \>2.0 units/kg). LS means of change from baseline were calculated using MMRM with investigator, baseline HbA1c (≤8% or \>8%), baseline TDD (≤300 or \>300 units), treatment (TID or BID), visit, and treatment-by-visit interaction as fixed effects and baseline body weight as a covariate.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kg
Change From Baseline to Week 24 in Body Weight Based on Baseline TDD Insulin ≥2.0 Units/kg and <2.0 Units/kg
kgHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
Baseline TDD insulin ≤2.0 units/kg (n=50, 46)6.11 ± 0.886.09 ± 0.93
Baseline TDD insulin >2.0 units/kg (n=112, 115)5.08 ± 0.444.40 ± 0.43

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Human Regular U-500 Insulin TID—28/162 (17.3%)80/162 (49.4%)
Human Regular U-500 Insulin BID—27/163 (16.6%)94/163 (57.7%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
HypoglycaemiaMetabolism and nutrition disorders3/1626/163
Acute myocardial infarctionCardiac disorders3/1621/163
Cardiac failure congestiveCardiac disorders1/1623/163
PneumoniaInfections and infestations1/1623/163
Chest painGeneral disorders2/1622/163
CellulitisInfections and infestations2/1621/163
Renal failure acuteRenal and urinary disorders0/1622/163
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1622/163
Atrial fibrillationCardiac disorders1/1620/163
Coronary artery diseaseCardiac disorders1/1621/163
Most frequent other events
Most frequent other events
EventHuman Regular U-500 Insulin TIDHuman Regular U-500 Insulin BID
NasopharyngitisInfections and infestations13/16217/163
Upper respiratory tract infectionInfections and infestations13/1629/163
HeadacheNervous system disorders13/1626/163
VomitingGastrointestinal disorders4/16211/163
DiarrhoeaGastrointestinal disorders6/16210/163
Oedema peripheralGeneral disorders6/16210/163
Pain in extremityMusculoskeletal and connective tissue disorders3/16210/163
BronchitisInfections and infestations9/1625/163
DyspnoeaRespiratory, thoracic and mediastinal disorders9/1627/163
NauseaGastrointestinal disorders4/1629/163

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BIDTotal
Mean55.31 ± 10.5155.50 ± 9.0355.41 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BIDTotal
Female7974153
Male8389172
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BIDTotal
Hispanic or Latino323062
Not Hispanic or Latino130133263
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BIDTotal
American Indian or Alaska Native314
Asian246
Native Hawaiian or Other Pacific Islander022
Black or African American211940
White133133266
More than one race347
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Human Regular U-500 Insulin TIDHuman Regular U-500 Insulin BIDTotal
United States146149295
Puerto Rico161430
08

Study locations

39 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mobile, Alabama 36617, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Little Rock, Arkansas 72205, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Concord, California 94520, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fresno, California 93720, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jacksonville, Florida 32216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33619, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    West Palm Beach, Florida 33401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Crystal Lake, Illinois 60012, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Des Moines, Iowa 50314, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Topeka, Kansas 66606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40206, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bangor, Maine 04401, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Baltimore, Maryland 21204, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, Missouri 65212, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Missouri 65807, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68131, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89148, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashua, New Hampshire 03063, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, North Carolina 27713, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenville, North Carolina 27834, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oklahoma City, Oklahoma 73104, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania 19107, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pittsburgh, Pennsylvania 15224, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chattanooga, Tennessee 37411, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nashville, Tennessee 37212, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beaumont, Texas 77701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75390, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Norfolk, Virginia 23507, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Federal Way, Washington 98003, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Olympia, Washington 98502, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Renton, Washington 98057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spokane, Washington 99202, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tacoma, Washington 98405, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bayamon, 00956, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Lomas, 00921, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Manati, 00674, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00917-3104, Puerto Rico
09

References and documents

Publications

  • Kabul S, Hood RC, Duan R, DeLozier AM, Settles J. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial. Health Qual Life Outcomes. 2016 Sep 30;14(1):139. doi: 10.1186/s12955-016-0541-4. PubMed 27716283 ↗
  • Mari A, Rosenstock J, Ma X, Li YG, Jackson JA. OPTIMIZED HUMAN REGULAR U-500 INSULIN TREATMENT IMPROVES beta-CELL FUNCTION IN SEVERELY INSULIN-RESISTANT PATIENTS WITH LONG-STANDING TYPE 2 DIABETES AND HIGH INSULIN REQUIREMENTS. Endocr Pract. 2015 Dec;21(12):1344-52. doi: 10.4158/EP15898.OR. Epub 2015 Aug 26. Erratum In: Endocr Pract. 2016 May;22(5):646. doi: 10.4158/1934-2403-22.5.646. PubMed 26307903 ↗
  • Hood RC, Arakaki RF, Wysham C, Li YG, Settles JA, Jackson JA. TWO TREATMENT APPROACHES FOR HUMAN REGULAR U-500 INSULIN IN PATIENTS WITH TYPE 2 DIABETES NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH-DOSE U-100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS: A RANDOMIZED, TITRATION-TO-TARGET CLINICAL TRIAL. Endocr Pract. 2015 Jul;21(7):782-93. doi: 10.4158/EP15612.OR. Epub 2015 Mar 26. Erratum In: Endocr Pract. 2016 Jul;22(7):905. doi: 10.4158/1934-2403-22.7.905. Dosage error in article text. PubMed 25813411 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2013
First posted
Jan 24, 2013
Start
Feb 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
May 12, 2015
Last update
Sep 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01774968
Responsible party
Sponsor
First posted
Jan 24, 2013
Start date
Feb 2013
Primary completion
May 2014
Completion
May 2014
Results posted
May 12, 2015
Last update
Sep 22, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion